Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20, Nivolumab, and Ipilimumab in Advanced Uveal Melanoma
NCT03922880Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2019
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pegargiminase in Uveal melanoma (UM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Safety as assessed by CTCAE version 5.0 at 3 years. Started Apr 2019; status: completed.
02
Drugs
Pegargiminase
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03922880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922880.